株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

抗うつ薬、デバイス、治療法の世界市場予測

GLOBAL ANTI-DEPRESSANT DRUGS, DEVICES, AND THERAPIES MARKET FORECAST 2017-2025

発行 Inkwood Research 商品コード 535790
出版日 ページ情報 英文 172 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.21円で換算しております。
Back to Top
抗うつ薬、デバイス、治療法の世界市場予測 GLOBAL ANTI-DEPRESSANT DRUGS, DEVICES, AND THERAPIES MARKET FORECAST 2017-2025
出版日: 2017年08月10日 ページ情報: 英文 172 Pages
概要

当レポートでは、抗うつ薬、デバイス、治療法の世界市場について調査し、全体的な市場動向、抗うつ薬・メンタルヘルス用デバイス・治療法・地域別の詳細動向、市場規模の推移と予測、成長促進・阻害要因ならびに市場機会・課題の分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

第1章 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

  • 要旨
  • 主な調査結果

第4章 市場の決定要因

  • 促進要因
  • 阻害要因
  • 機会
  • 課題

第5章 抗うつ薬、デバイス、治療の世界市場:市場区分

  • コンポーネント別
    • 抗うつ薬市場
      • セロトニン・ノルアドレナリン再取り込み阻害薬(SNRI)
      • ノルアドレナリン・ドーパミン再取り込み阻害薬(NDRI)
      • 非定型抗うつ薬
      • モノアミン酸化酵素阻害薬
      • その他
    • メンタルヘルス用デバイス市場
      • 脳深部刺激装置(DBS)
      • 頭蓋電気刺激装置(CES)
      • 経頭蓋磁気刺激装置(TMS)
    • 治療法市場
      • 認知行動療法(CBT)
      • 電気痙攣療法(ECT)
      • 理性感情行動療法(REBT)
      • その他の治療法

第6章 市場分析

  • ファイブフォース分析
  • 予測分析
  • バリューチェーン分析
    • 抗うつ薬のバリューチェーン分析
    • 治療デバイスのバリューチェーン
  • 主な購買基準
  • 市場機会のマトリクス
  • ベンダー情勢

第7章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • EUの医療費償還政策・規制
    • 英国
    • フランス
    • ドイツ
    • スペイン
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他
  • その他の地域

第8章 企業プロファイル

  • 競合情勢
    • 主な戦略・分析
    • 市場シェアの分析
    • 主要企業の分析
  • ABBOT LABORATORIES
  • ALLERGAN PLC
  • BOEHRINGER INGELHEIM GMBH
  • BRAINSWAY
  • CYBERONICS INC
  • ELI LILLY AND COMPANY
  • F. HOFFMANN-LA ROCHE LTD
  • GLAXOSMITHKLINE
  • H. LUNDBECK AS
  • MAYO CLINIC
  • NEURONETICS
  • PFIZER
  • SANOFI
  • SUN PHARMACEUTICALS
  • TEVA PHARMACEUTICALS INDUSTRIES

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: 6732

KEY FINDINGS

The Global Anti-depressant drugs, devices, and therapies market is anticipated to grow at a CAGR of 2.12% over the forecast period of 2017- and 2025. The revenue generated by the market is expected to increase from $ 16442 million in 2016 and reach $19712 million by 2025. The antidepressant drugs, devices, and therapies market is primarily driven because of factors such as a shift in the market from branded to generic drugs, a growing consciousness of depression as a medical disorder and the surge in sales of antidepressants in the past few years.

MARKET INSIGHTS

The market is segmented into types of antidepressants drugs, types of devices and the types of therapies. The Antidepressants drugs are further segmented into Serotonin and norepinephrine reuptake inhibitors (SNRIs), atypical antidepressants, Norepinephrine and dopamine reuptake inhibitors (NDRIs), Tricyclic antidepressants (TCA), Monoamine oxidase inhibitors (MAOIs) etc. The Devices are further segmented into Fisher Wallace Stimulators, Deep Brain Stimulators, Transcranial Magnetic Stimulator, etc. Also, the Therapies segment is further sub-divided into Electroconvulsive Therapy (ECT), Cognitive Behavior Therapy (CBT), Rational-emotive behavior therapy (REBT), etc.

The high cost of depression therapies coupled with the lack of medical insurance coverage for them is a major factor restraining the market growth. However, with the rising awareness about depression being a medical condition, the market is expected to show a huge promise during the forecasted years.

REGIONAL INSIGHTS

Geographically, the global anti-depressant drugs, devices, and therapies market is segmented into:

North America - U.S. & Canada

Asia-Pacific - China, India, Japan, Australia, Rest of APAC

Europe - UK, France, Germany, Spain, Rest of Europe

Rest of World

The North American market is expected to hold the biggest share by 2025 on account of its developed healthcare system and increased expenditure on mental health treatment. Major players such as Eli Lilly, Forest Laboratories, and Pfizer are based in North America. However, this market is facing a possibility of dilution on account of the patent expiry of most of the prescribed drugs. On the contrary, the Asia-Pacific market is expected to be the fastest-growing region for the anti-depressant drugs, devices, and therapies market. The level of awareness regarding depression is steadily increasing in countries such as India, China, Japan, and Korea, thus making this region a prospective market in the coming years.

COMPETITIVE INSIGHTS

Pfizer Inc. is a research-based, global biopharmaceutical company that deals with vaccines, medicines, and consumer healthcare products. TEVA Pharmaceutical Industries is another prominent generic pharmaceutical company that is engaged in the development, production, and marketing of generic, proprietary branded pharmaceuticals and active pharmaceutical ingredients. Some of the other major players include Sun Pharmaceuticals, Eli Lily, Neuronetics, Allergan Plc, Abbot Laboratories, Brainsway, Cyberonics Inc, etc.

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION
  • 2.5. ESTIMATION METHODOLOGY

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
    • 3.1.1. KEY FINDINGS
      • 3.1.1.1. STIFF COMPETITION BETWEEN GENERIC AND BRANDED DRUGS
      • 3.1.1.2. RISE IN THE NUMBER OF DEPRESSION PATIENTS AND INCREASING AWARENESS LEVEL OF THE ASIAN CONSUMERS
      • 3.1.1.3. A SHIFT IN THE MARKET FROM BRANDED TO GENERIC DRUGS

4. MARKET DYNAMICS

  • 4.1. DRIVERS
    • 4.1.1. BRANDED DRUGS ARE OUTPERFORMING DUE TO HIGH COST COMPARED TO GENERIC DRUGS
    • 4.1.2. SWELLING CONSCIOUSNESS OF DEPRESSION AS A MEDICAL DISORDER
    • 4.1.3. SURGE IN SALES OF ANTIDEPRESSANTS
  • 4.2. RESTRAINTS
    • 4.2.1. HIGH PRICE OF THE DEPRESSION THERAPY
    • 4.2.2. PATENT EXPIRATION FACED BY THE COMPANIES
    • 4.2.3. DELAY IN PRODUCT LAUNCHES
  • 4.3. CHALLENGES
    • 4.3.1. STIFF COMPETITION FROM THE GENERIC DRUG MAKERS
  • 4.4. OPPORTUNITIES
    • 4.4.1. HUGE MARKET POTENTIAL
    • 4.4.2. MORE INTENDED FOR PERSONNEL THERAPY AND DEVICES TREATMENT

5. SEGMENTATION

  • 5.1. MARKET BY COMPONENTS 2017-2025
    • 5.1.1. MARKET BY ANTIDEPRESSANTS 2017-2025
      • 5.1.1.1. SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)
      • 5.1.1.2. NOREPINEPHRINE AND DOPAMINE REUPTAKE INHIBITORS (NDRIS)
      • 5.1.1.3. ATYPICAL ANTIDEPRESSANTS
      • 5.1.1.4. MONOAMINE OXIDASE INHIBITORS (MAOIS)
      • 5.1.1.5. OTHER MEDICATIONS
    • 5.1.2. MARKET BY MENTAL HEALTH DEVICES
      • 5.1.2.1. GLOBAL DEEP BRAIN SIMULATOR MARKET
      • 5.1.2.2. FISHER WALLACE STIMULATOR
      • 5.1.2.3. TRANSCRANIAL MAGNETIC SIMULATOR (TMS)
      • 5.1.2.4. OTHER DEVICES
    • 5.1.3. MARKET BY THERAPIES 2017-2025
      • 5.1.3.1. COGNITIVE BEHAVIOR THERAPY (CBT)
      • 5.1.3.2. ELECTROCONVULSIVE THERAPY (ECT)
      • 5.1.3.3. RATIONAL EMOTIVE BEHAVIOR THERAPY (REBT)
      • 5.1.3.4. OTHER THERAPIES

6. KEY ANALYTICALS

  • 6.1. PORTERS 5 FORCES MODEL
    • 6.1.1. THREAT OF NEW ENTRANTS
    • 6.1.2. THREAT OF SUBSTITUTE PRODUCTS
    • 6.1.3. BARGAINING POWER OF BUYER
    • 6.1.4. BARGAINING POWER OF SUPPLIER
    • 6.1.5. INTENSITY OF COMPETITIVE RIVALRY
  • 6.2. ESTIMATION ANALYSIS
    • 6.2.1. INCREASING PREVALENCE OF MENTAL HEALTH PROBLEMS
    • 6.2.2. RISING HEALTHCARE EXPENDITURE ACROSS THE GLOBE
    • 6.2.3. RISING GERIATRIC POPULATION
  • 6.3. VALUE CHAIN ANALYSIS
    • 6.3.1. FOR DRUGS
      • 6.3.1.1. MANUFACTURERS
      • 6.3.1.2. DISTRIBUTORS
      • 6.3.1.3. RETAILERS
      • 6.3.1.4. END-USERS
    • 6.3.2. FOR DEVICES
      • 6.3.2.1. MANUFACTURERS
      • 6.3.2.2. DISTRIBUTORS
      • 6.3.2.3. END-USERS
  • 6.4. KEY BUYING CRITERIA
  • 6.5. OPPORTUNITY MATRIX
  • 6.6. VENDOR LANDSCAPE

7. GEOGRAPHY

  • 7.1. NORTH AMERICA
    • 7.1.1. UNITED STATES
    • 7.1.2. CANADA
  • 7.2. EUROPE
    • 7.2.1. REGULATIONS AND REIMBURSEMENT POLICIES IN THE EUROPEAN UNION
    • 7.2.2. UNITED KINGDOM
    • 7.2.3. FRANCE
    • 7.2.4. GERMANY
    • 7.2.5. SPAIN
    • 7.2.6. REST OF THE EUROPE
  • 7.3. ASIA PACIFIC
    • 7.3.1. CHINA
    • 7.3.2. INDIA
    • 7.3.3. JAPAN
    • 7.3.4. AUSTRALIA
    • 7.3.5. REST OF ASIA PACIFIC
  • 7.4. REST OF WORLD

8. COMPANY PROFILE

  • 8.1. COMPETITIVE ANALYSIS
    • 8.1.1. KEY STRATEGIES AND ANALYSIS
    • 8.1.2. MARKET SHARE ANALYSIS
    • 8.1.3. TOP COMPANY ANALYSIS
  • 8.2. ABBOT LABORATORIES
  • 8.3. ALLERGAN PLC
  • 8.4. BOEHRINGER INGELHEIM GMBH
  • 8.5. BRAINSWAY
  • 8.6. CYBERONICS INC
  • 8.7. ELI LILLY AND COMPANY
  • 8.8. F. HOFFMANN-LA ROCHE LTD
  • 8.9. GLAXOSMITHKLINE
  • 8.10. H. LUNDBECK AS
  • 8.11. MAYO CLINIC
  • 8.12. NEURONETICS
  • 8.13. PFIZER
  • 8.14. SANOFI
  • 8.15. SUN PHARMACEUTICALS
  • 8.16. TEVA PHARMACEUTICALS INDUSTRIES

TABLE LIST

  • TABLE # 1 GLOBAL ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET BY REGION 2017- 2025 ($ MILLION)
  • TABLE # 2 PREVALENCE OF DEPRESSION IN WESTERN EUROPE IN 2016
  • TABLE # 3 REGULATIONS AFFECTING DEPRESSION DRUGS AND THERAPY
  • TABLE # 4 LANDSCAPE OF DRUG EXPIRY AND LAUNCHES IN THE UNITED STATES
  • TABLE # 5 GLOBAL ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, BY COMPONENTS 2017-2025($ MILLION)
  • TABLE # 6 GLOBAL ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET BY ANTIDEPRESSANTS 2017-2025($ MILLION)
  • TABLE # 7 GLOBAL ANTIDEPRESSANTS MARKET BY GEOGRAPHY 2017-2025($ MILLION)
  • TABLE # 8 MAJOR PLAYERS IN THE SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS MARKET
  • TABLE # 9 PRICE OF BUPROPION (WELLBUTRIN)
  • TABLE # 10 MAJOR PLAYERS OF THE NOREPINEPHRINE AND DOPAMINE REUPTAKE INHIBITORS
  • TABLE # 11 PRICE OF TRAZODONE OF DIFFERENT STRENGTH
  • TABLE # 12 MAJOR PLAYERS OF THE ATYPICAL ANTIDEPRESSANTS MARKET
  • TABLE # 13 PRICE OF TOFRANIL OF DIFFERENT STRENGTH
  • TABLE # 14 MAJOR PLAYERS OF THE TRICYCLIC ANTIDEPRESSANTS MARKET
  • TABLE # 15 PRICE OF TRANYLCYPROMINE (PARNATE)
  • TABLE # 16 MAJOR PLAYERS OF THE MONOAMINE OXIDASE INHIBITORS (MAOIS) MARKET
  • TABLE # 17 MAJOR PLAYERS OF THE OTHER ANTIDEPRESSANTS MARKET
  • TABLE # 18 GLOBAL DEPRESSION MARKET BY MENTAL HEALTH DEVICES 2017-2025($ MILLION)
  • TABLE # 19 GLOBAL MENTAL HEALTH DEVICES MARKET BY REGIONS 2017-2025($ MILLION)
  • TABLE # 20 MAJOR PLAYERS OF THE DEEP BRAIN SIMULATION MARKET
  • TABLE # 21 MAJOR PLAYERS IN THE FISHER WALLACE SIMULATOR MARKET
  • TABLE # 22 MAJOR PLAYERS OF THE TRANSCRANIAL MAGNETIC SIMULATOR MARKET
  • TABLE # 23 MAJOR PLAYERS OF THE OTHER DEVICES MARKET
  • TABLE # 24 GLOBAL THERAPIES MARKET 2017-2025($ MILLION)
  • TABLE # 25 GLOBAL THERAPIES MARKET BY REGION WISE 2017-2025($ MILLION)
  • TABLE # 26 GLOBAL ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET BY GEOGRAPHY 2017-2025($ MILLION)
  • TABLE # 27 NORTH AMERICA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET, 2017-2025 ($ MILLION)
  • TABLE # 28 EUROPE GLOBAL ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET BY COUNTRIES 2017-2025($ MILLION)
  • TABLE # 29 ASIA PACIFIC ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
  • TABLE # 30 KEY STRATEGIES FOLLOWED BY COMPANIES WITHIN ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET
  • FIGURE LIST
  • FIGURE # 1 ADULTS AVAILED MENTAL HEALTH TREATMENT IN THE US
  • FIGURE # 2 DYSTHYMIC DISORDER IN THE US
  • FIGURE # 3 GLOBAL ANTIDEPRESSANTS DRUG MARKET IN 2017-2025($ MILLION)
  • FIGURE # 4 ASIA PACIFIC ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 5 SAVINGS THROUGH GENERIC DRUG USAGE IN THE UNITED STATES IN 2010-2016 ($ BILLION)
  • FIGURE # 6 GLOBAL ANTIDEPRESSANTS MARKET 2016 & 2025($ MILLION)
  • FIGURE # 7 GLOBAL SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS MARKET 2017-2025($ MILLION)
  • FIGURE # 8 GLOBAL NDRIS MARKET 2017-2025($ MILLION)
  • FIGURE # 9 GLOBAL ATYPICAL ANTIDEPRESSANTS MARKET 2017-2025($ MILLION)
  • FIGURE # 10 GLOBAL TRICYCLIC ANTIDEPRESSANTS MARKET 2017-2025 ($ MILLION)
  • FIGURE # 11 GLOBAL MAOIS MARKET 2017-2025 ($ MILLION)
  • FIGURE # 12 GLOBAL OTHER ANTIDEPRESSANTS MARKET 2017-2025($ MILLION)
  • FIGURE # 13 GLOBAL MENTAL HEALTH DEVICES MARKET 2016 & 2025($ MILLION)
  • FIGURE # 14 GLOBAL DEEP BRAIN SIMULATION MARKET 2017-2025($ MILLION)
  • FIGURE # 15 GLOBAL FISHER WALLACE SIMULATOR MARKET 2017-2025($ MILLION)
  • FIGURE # 16 GLOBAL TRANSCRANIAL MAGNETIC SIMULATORMARKET 2017-2025($MILLION)
  • FIGURE # 17 GLOBAL TRANSCRANIAL MAGNETIC SIMULATORMARKET 2017-2025($ MILLION)
  • FIGURE # 18 GLOBAL THERAPIES MARKET 2016 & 2025($ MILLION)
  • FIGURE # 19 GLOBAL COGNITIVE BEHAVIOR MARKET 2017-2025($ MILLION)
  • FIGURE # 20 GLOBAL ELECTROCONVULSIVE THERAPY MARKET 2017-2025($MILLION)
  • FIGURE # 21 GLOBAL RATIONAL EMOTIVE BEHAVIOUR THERAPY MARKET 2017-2025($ MILLION)
  • FIGURE # 22 GLOBAL OTHER THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 23 PREVALENCE OF MENTAL HEALTH DISORDERS ACROSS THE GLOBE BETWEEN PERIOD 2012 AND 2020 (MILLION)
  • FIGURE # 24 RISING GERIATRIC POPULATION ACROSS THE GLOBE FOR PERIOD 2014-2020 (MILLION)
  • FIGURE # 25 VALUE CHAIN OF ANTIDEPRESSANT DRUGS
  • FIGURE # 26 VALUE CHAIN ANALYSIS FOR DEVICE MARKET
  • FIGURE # 27 GLOBAL ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET BY GEOGRAPHY 2016 & 2025($ MILLION)
  • FIGURE # 28 UNITED STATES ANTIDEPRESSANTS DRUGS, DEVICES, AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 29 CANADA ANTIDEPRESSANTS DRUGS, DEVICES, AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 30 EUROPEAN ANTIDEPRESSANTS DRUGS, DEVICES, AND THERAPIES MARKET 2016 & 2025(%)
  • FIGURE # 31 UNITED KINGDOM ANTIDEPRESSANTS DRUGS, DEVICES, AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 32 FRANCE ANTIDEPRESSANTS DRUGS, DEVICES, AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 33 GERMANY ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 34 SPAIN GLOBAL ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 35 CHINA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 36 INDIA ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 37 JAPAN ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 38 AUSTRALIA ANTIDEPRESSANTS DRUGS, DEVICES, AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 39 REST OF ASIA PACIFIC ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($MILLION)
  • FIGURE # 40 REST OF WORLD ANTIDEPRESSANTS DRUGS, DEVICES AND THERAPIES MARKET 2017-2025($ MILLION)
  • FIGURE # 41 MARKET SHARE OF ANTIDEPRESSANTS DRUG MANUFACTURERS (PERCENTAGE OF SALES), 2016
Back to Top